Steve Reed uses familiar strategy to build a new biotech

In a follow-up to yesterday's news that Immune Design had raised a $32 million round to fuel its work on a new generation of vaccines, CEO Steve Reed talked to Xconomy's Luke Timmerman about his plans for the future. So far, explains Timmerman, Immune Design has been sticking with a familiar game plan: Build a team, get some supporting data, get into the clinic and then start forging partnerships with Big Pharma outfits. That's exactly how Reed went about the business of building Corixa,...